Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct 30;10(10):CD014851.
doi: 10.1002/14651858.CD014851.

Pharmacological interventions for peripartum cardiomyopathy

Michail Papapanou  1   2 , Dennis Vaidakis  3 , Themistoklis Paraskevas  4 , Theodoros N Sergentanis  5 , Charalampos S Siristatidis  6
Affiliations

Pharmacological interventions for peripartum cardiomyopathy

Michail Papapanou et al. Cochrane Database Syst Rev. .

Abstract

This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To assess the effectiveness and safety of available pharmacological interventions for the care of women diagnosed with PPCM.

PubMed Disclaimer

Conflict of interest statement

MP, DV, TP, TNS, and CSS have no conflicts of interest to disclose concerning the conduct, analysis, and publication of studies that could be included in the specific review.

DV, TP, and TNS have declared that they have no conflict of interest.

CSS has special permission from the National and Kapodistrian University of Athens to run his private practice from 2003 till now, but this is unrelated to the specific review.

MP has received two grants from the World Health Organization unrelated to the present review.

References

Additional references

Adedinsewo 2023
    1. Adedinsewo DA, Morales-Lara AC, Dugan J, Garzon-Siatoya WT, Yao X, Johnson PW, et al. Screening for peripartum cardiomyopathies using artificial intelligence in Nigeria (SPEC-AI Nigeria): Clinical trial rationale and design. American Heart Journal 2023;261:64-74. [DOI: ] - PubMed
Al Riyami 2023
    1. Al Riyami N, Al Khayari S, Al Zadjali R, Machado L, Al Madhani A, Al Lawati H. Incidence, risk factors, maternal and neonatal outcomes of peripartum cardiomyopathy (PPCM) in Oman. Global Heart 2023;18(1):23. [DOI: 10.5334/gh.1198] - DOI - PMC - PubMed
Arany 2016
    1. Arany Z, Elkayam U. Peripartum cardiomyopathy. Circulation 2016;133(14):1397-1409. [DOI: 10.1161/CIRCULATIONAHA.115.020491] - DOI - PubMed
Araujo‐Jorge 2022
    1. Araujo-Jorge TC, Rivera MT, Vanderpas J, Garzoni LR, Carvalho ACC, Waghabi MC, et al. Selenium, TGF-beta and infectious endemic cardiopathy: lessons from benchwork to clinical application in Chagas disease. Biomolecules 2022;12(3):349. [DOI: 10.3390/biom12030349] - DOI - PMC - PubMed
Arrigo 2021
    1. Arrigo M, Blet A, Mebazaa A. Bromocriptine for the treatment of peripartum cardiomyopathy: welcome on BOARD. European Heart Journal 2017;38(35):2680-2682. [DOI: 10.1093/eurheartj/ehx428] - DOI - PubMed
Asad 2018
    1. Asad ZUA, Maiwand M, Farah F, Dasari TW. Peripartum cardiomyopathy: A systematic review of the literature. Clinical Cardiology 2018;41(5):693-697. [DOI: ] - PMC - PubMed
Bauersachs 2016
    1. Bauersachs J, Arrigo M, Hilfiker-Kleiner D, Veltmann C, Coats AJ, Crespo-Leiro MG, et al. Current management of patients with severe acute peripartum cardiomyopathy: practical guidance from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy. European Journal of Heart Failure 2016;18(9):1096-1105. [DOI: ] - PubMed
Borenstein 2008
    1. Borenstein M, Hedges LV, Higgins JP, Rothstein HR. Introduction to Meta-Analysis. John Wiley & Sons, 2009. [DOI: 10.1002/9780470743386] - DOI
Boutron 2023
    1. Boutron I, Page MJ, Higgins JPT, Altman DG, Lundh A, Hróbjartsson A. Chapter 7: Considering bias and conflicts of interest among the included studies. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023). Cochrane, 2023. Available from training.cochrane.org/handbook/archive/v6.4.
Cénac 1992
    1. Cénac A, Simonoff M, Moretto P, Djibo A. A low plasma selenium is a risk factor for peripartum cardiomyopathy. A comparative study in Sahelian Africa. International Journal of Cardiology 1992;36(1):57-59. [DOI: 10.1016/0167-5273(92)90108-F] - DOI - PubMed
Davis 2020
    1. Davis MB, Arany Z, McNamara DM, Goland S, Elkayam U. Peripartum cardiomyopathy: JACC state-of-the-art review. Journal of the American College of Cardiology 2020;75(2):207-221. [DOI: 10.1016/j.jacc.2019.11.014] - DOI - PubMed
Deeks 2023
    1. Deeks JJ, Higgins JPT, Altman DG, editor(s). Chapter 10: Analysing data and undertaking meta-analyses. In: In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023). Cochrane, 2023. Available from training.cochrane.org/handbook/archive/v6.4.
Ersbøll 2016
    1. Ersbøll AS, Damm P, Gustafsson F, Vejlstrup NG, Johansen M. Peripartum cardiomyopathy: a systematic literature review. Acta Obstetricia et Gynecologica Scandinavica 2016;95(11):1205-1219. [DOI: ] - PubMed
Francis 1983
    1. Francis GS, Parks R, Cohn JN. The effects of bromocriptine in patients with congestive heart failure. American Heart Journal 1983;106(1):100-106. [DOI: 10.1016/0002-8703(83)90446-5] - DOI - PubMed
GRADEpro GDT [Computer program]
    1. GRADEpro GDT. Version accessed 9 October 2024. Hamilton (ON): McMaster University (developed by Evidence Prime), 2024. Available at https://gradepro.org/.
Guyatt 2011
    1. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction - GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology 2011;64(4):383-394. [DOI: 10.1016/j.jclinepi.2010.04.026] - DOI - PubMed
Haghikia 2013
    1. Haghikia A, Podewski E, Libhaber E, Labidi S, Fischer D, Roentgen P, et al. Phenotyping and outcome on contemporary management in a German cohort of patients with peripartum cardiomyopathy. Basic Research in Cardiology 2013;108(4):366. [DOI: 10.1007/s00395-013-0366-9] - DOI - PMC - PubMed
Haghikia 2015
    1. Haghikia A, Kaya Z, Schwab J, Westenfeld R, Ehlermann P, Bachelier K, et al. Evidence of autoantibodies against cardiac troponin I and sarcomeric myosin in peripartum cardiomyopathy. Basic Research in Cardiology 2015;110(6):60. [DOI: 10.1007/s00395-015-0517-2] - DOI - PubMed
Halkein 2013
    1. Halkein J, Tabruyn SP, Ricke-Hoch M, Haghikia A, Nguyen NQ, Scherr M, et al. MicroRNA-146a is a therapeutic target and biomarker for peripartum cardiomyopathy. Journal of Clinical Investigation 2013;123(5):2143-2154. [DOI: 10.1172/JCI64365] - DOI - PMC - PubMed
Higgins 2023a
    1. Higgins JPT, Eldridge S, Li T, editor(s). Chapter 23: Including variants on randomized trials. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023). Cochrane, 2023. Available from training.cochrane.org/handbook/archive/v6.4.
Higgins 2023b
    1. Higgins JPT, Eldridge S, Li T, editor(s). Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023). Cochrane, 2023. Available from training.cochrane.org/handbook/archive/v6.4.
Higgins 2023c
    1. Higgins JP, Li T, Deeks JJ. Chapter 6: Choosing effect measures and computing estimates of effect. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023). Cochrane, 2023. Available from training.cochrane.org/handbook/archive/v6.4.
Hilfiker‐Kleiner 2007
    1. Hilfiker-Kleiner D, Kaminski K, Podewski E, Bonda T, Schaefer A, Sliwa K, et al. A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy. Cell 2007;128(3):589-600. [DOI: 10.1016/j.cell.2006.12.036. PMID: 17289576] - PubMed
Hoevelmann 2022
    1. Hoevelmann J, Engel ME, Muller E, Hohlfeld A, Böhm M, Sliwa K, et al. A global perspective on the management and outcomes of peripartum cardiomyopathy: a systematic review and meta-analysis. European Journal of Heart Failure 2022;24(9):1719-1736. [DOI: ] - PubMed
Holt 2010
    1. Holt RI, Barnett AH, Bailey CJ. Bromocriptine: old drug, new formulation and new indication. Diabetes, Obesity and Metabolism 2010;12:1048-1057. [DOI: 10.1111/j.1463-1326.2010.01304.x] - DOI - PubMed
Hosseinpour 2022
    1. Hosseinpour A, Hosseinpour H, Kheshti F, Abdollahifard S, Attar A. Prognostic value of various markers in recovery from peripartum cardiomyopathy: a systematic review and meta-analysis. ESC Heart Failure 2022;9(5):3483-3495. [DOI: ] - PMC - PubMed
Hu 2007
    1. Hu CL, Li YB, Zou YG, Zhang JM, Chen JB, Liu J, et al. Troponin T measurement can predict persistent left ventricular dysfunction in peripartum cardiomyopathy. Heart 2007;93(4):488. [DOI: 10.1136/hrt.2006.087387] - DOI - PMC - PubMed
Karaye 2015
    1. Karaye KM, Yahaya IA, Lindmark K, Henein MY. Serum selenium and ceruloplasmin in Nigerians with peripartum cardiomyopathy. International Journal of Molecular Sciences 2015;16(4):7644-7654. [DOI: 10.3390/ijms16047644] - DOI - PMC - PubMed
Karaye 2021a
    1. Karaye KM, Sa'idu H, Balarabe SA, Ishaq NA, Sanni B, Abubakar H, et al. Selenium supplementation in patients with peripartum cardiomyopathy: a proof-of-concept trial. BMC Cardiovascular Disorders 2021;20(1):457. [DOI: 10.1186/s12872-020-01739-z] - DOI - PMC - PubMed
Karaye 2021b
    1. Karaye KM, Ishaq NA, Sai'du H, Balarabe SA, Ahmed BG, Adamu UG, et al, Peripartum Cardiomyopathy in Nigeria (PEACE) Registry Investigators. Disparities in clinical features and outcomes of peripartum cardiomyopathy in high versus low prevalent regions in Nigeria. ESC Heart Failure 2021;8(4):3257-3267. [DOI: ] - PMC - PubMed
Kerpen 2019
    1. Kerpen K, Koutrolou-Sotiropoulou P, Zhu C, Yang J, Lyon JA, Lima FV, et al. Disparities in death rates in women with peripartum cardiomyopathy between advanced and developing countries: a systematic review and meta-analysis. Archives of Cardiovascular Diseases 2019;112(3):187-198. [DOI: ] - PubMed
Koenig 2018
    1. Koenig T, Bauersachs J, Hilfiker-Kleiner D. Bromocriptine for the treatment of peripartum cardiomyopathy. Cardiac Failure Review 2018;4(1):46-49. [DOI: 10.15420/cfr.2018:2:2] - DOI - PMC - PubMed
Koerber 2023
    1. Koerber D, Khan S, Kirubarajan A, Spivak A, Wine R, Matelski J, et al. Meta-analysis of long-term (>1 year) cardiac outcomes of peripartum cardiomyopathy. American Journal of Cardiology 2023;194:71-77. [DOI: 10.1016/j.amjcard.2023.01.043] - DOI - PubMed
Kolte 2014
    1. Kolte D, Khera S, Aronow WS, Palaniswamy C, Mujib M, Ahn C, et al. Temporal trends in incidence and outcomes of peripartum cardiomyopathy in the United States: a nationwide population-based study. Journal of the American Heart Association 2014;3(3):e001056. [DOI: 10.1161/JAHA.114.001056] - DOI - PMC - PubMed
Koziol 2023
    1. Koziol KJ, Aronow WS. Peripartum cardiomyopathy: current understanding of pathophysiology, diagnostic workup, management, and outcomes. Current Problems in Cardiology 2023;48(8):101716. [DOI: ] - PubMed
Kumar 2022
    1. Kumar A. Prolactin inhibition in peripartum cardiomyopathy: systematic review and meta-analysis. Current Problems in Cardiology 2023;48:101461. [DOI: 10.1016/j.cpcardiol.2022.101461] - DOI - PMC - PubMed
Lefebvre 2022
    1. Lefebvre C, Glanville J, Briscoe S, Featherstone R, Littlewood A, Marshall C, et al. Chapter 4: Searching for and selecting studies. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook/archive/v6.3/chapter-04.
McKenzie 2023
    1. McKenzie JE, Brennan SE. Chapter 12: Synthesizing and presenting findings using other methods. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023). Cochrane, 2023. Available from training.cochrane.org/handbook/archive/v6.4.
Molitch 2017
    1. Molitch ME. Diagnosis and treatment of pituitary adenomas: A review. JAMA 2017;317:516-524. [DOI: 10.1001/jama.2016.19699] - DOI - PubMed
Mujkanovic 2023
    1. Mujkanovic J. Review of randomized controlled trials in patients with peripartum cardiomyopathy. Current Cardiology Reviews 2023;19:e230822207933. [DOI: 10.2174/1573403X18666220823151854] - DOI - PMC - PubMed
Okeke 2013
    1. Okeke T, Ezenyeaku C, Ikeako L. Peripartum cardiomyopathy. Annals of Medical and Health Sciences Research 2013;3(3):313-319. [DOI: 10.4103/2141-9248.117925] - DOI - PMC - PubMed
Pachariyanon 2023
    1. Pachariyanon P, Bogabathina H, Jaisingh K, Modi M, Modi K. Long-term outcomes of women with peripartum cardiomyopathy having subsequent pregnancies. Journal of the American College of Cardiology 2023;82(1):16-26. [DOI: ] - PubMed
Page 2023
    1. Page MJ, Higgins JPT, Sterne JAC. Chapter 13: Assessing risk of bias due to missing results in a synthesis. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023). Cochrane, 2023. Available from training.cochrane.org/handbook/archive/v6.4.
Patten 2012
    1. Patten IS, Rana S, Shahul S, Rowe GC, Jang C, Liu L, et al. Cardiac angiogenic imbalance leads to peripartum cardiomyopathy. Nature 2012;485(7398):333-338. [DOI: 10.1038/nature11040] - DOI - PMC - PubMed
Perez‐Lloret 2010
    1. Perez-Lloret S, Rascol O. Dopamine receptor agonists for the treatment of early or advanced Parkinson’s disease. CNS Drugs 2010;24:941-968. [DOI: 10.2165/11537810-000000000-00000] - DOI - PubMed
Pfeffer 2023
    1. Pfeffer TJ, Mueller JH, Haebel L, Erschow S, Yalman KC, Talbot SR, et al. Cabergoline treatment promotes myocardial recovery in peripartum cardiomyopathy. ESC Heart Failure 2023;10(1):465-477. [DOI: ] - PMC - PubMed
Price 2014
    1. Price AK, Bridges RS. The effects of bromocriptine treatment during early pregnancy on postpartum maternal behaviors in rats. Developmental Psychobiology 2014;56(6):1431-1437. [DOI: 10.1002/dev.21224] - DOI - PMC - PubMed
Regitz‐Zagrosek 2018
    1. Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, Blomström-Lundqvist C, Cífková R, De Bonis M, et al, ESC Scientific Document Group. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy: The Task Force for the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). European Heart Journal 2018;39(34):3165-3241. [DOI: 10.1093/eurheartj/ehy340] - DOI - PubMed
RevMan 2024 [Computer program]
    1. Review Manager (RevMan). Version 7.12.0. The Cochrane Collaboration, 2024. Available at https://revman.cochrane.org.
Robbins 2023
    1. Robbins LS, Szychowski JM, Nassel A, Arora G, Armour EK, Walker Z, et al. Geographic disparities in peripartum cardiomyopathy outcomes. American Journal of Obstetrics & Gynecology MFM 2023;5(2):100788. [DOI: 10.1016/j.ajogmf.2022.100788] - DOI - PMC - PubMed
Schünemann 2023a
    1. Schünemann HJ, Higgins JPT, Vist GE, Glasziou P, Akl EA, Skoetz N, et al. Chapter 14: Completing ‘Summary of findings’ tables and grading the certainty of the evidence. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023). Cochrane, 2023. Available from training.cochrane.org/handbook/archive/v6.4.
Schünemann 2023b
    1. Schünemann HJ, Vist GE, Higgins JPT, Santesso N, Deeks JJ, Glasziou P, et al. Chapter 15: Interpreting results and drawing conclusions. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023). Cochrane, 2023. Available from training.cochrane.org/handbook/archive/v6.4.
Sliwa 2006
    1. Sliwa K, Förster O, Libhaber E, Fett JD, Sundstrom JB, Hilfiker-Kleiner D, et al. Peripartum cardiomyopathy: inflammatory markers as predictors of outcome in 100 prospectively studied patients. European Heart Journal 2006;27(4):441-446. [DOI: 10.1093/eurheartj/ehi481] - DOI - PubMed
Sliwa 2010
    1. Sliwa K, Blauwet L, Tibazarwa K, Libhaber E, Smedema JP, Becker A, et al. Evaluation of bromocriptine in the treatment of acute severe peripartum cardiomyopathy: a proof-of-concept pilot study. Circulation 2010;121(13):1465-1473. [DOI: 10.1161/CIRCULATIONAHA.109.901496] - DOI - PubMed
Sliwa 2017
    1. Sliwa K, Mebazaa A, Hilfiker-Kleiner D, Petrie MC, Maggioni AP, Laroche C, et al. Clinical characteristics of patients from the worldwide registry on peripartum cardiomyopathy (PPCM). European Journal of Heart Failure 2017;19(9):1131-1141. [DOI: ] - PubMed
Sterne 2019
    1. Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 2019;366:4896. - PubMed
Taylor 2023
    1. Taylor J, Yeung ACY, Ashton A, Faiz A, Guryev V, Fang B, et al. Transcriptomic comparison of human peripartum and dilated cardiomyopathy identifies differences in key disease pathways. Journal of Cardiovascular Development and Disease 2023;10(5):188. [DOI: 10.3390/jcdd10050188] - DOI - PMC - PubMed
Tromp 2023
    1. Tromp J, Jackson AM, Abdelhamid M, Fouad D, Youssef G, Petrie MC, et al, Investigators of the ESC EORP PPCM Registry. Thromboembolic events in peripartum cardiomyopathy: Results from the ESC EORP PPCM registry. European Journal of Heart Failure 2023;25(8):1464-1466. [DOI: ] - PubMed
Trongtorsak 2022
    1. Trongtorsak A. Effects of bromocriptine in peripartum cardiomyopathy: a systematic review and meta-analysis. Heart Failure Reviews 2022;27:533-543. [DOI: 10.1007/s10741-021-10185-8. Epub 2021] - PubMed
van Spaendonck‐Zwarts 2014
    1. Spaendonck-Zwarts KY, Posafalvi A, den Berg MP, Hilfiker-Kleiner D, Bollen IA, Sliwa K, et al. Titin gene mutations are common in families with both peripartum cardiomyopathy and dilated cardiomyopathy. European Heart Journal 2014;35(32):2165-2173. [DOI: 10.1093/eurheartj/ehu050] - DOI - PubMed
Ware 2016
    1. Ware JS, Li J, Mazaika E, Yasso CM, DeSouza T, Cappola TP, et al, IMAC-2 and IPAC Investigators. Shared genetic predisposition in peripartum and dilated cardiomyopathies. New England Journal of Medicine 2016;374(3):233-241. [DOI: 10.1056/NEJMoa1505517] - DOI - PMC - PubMed
Xu 2023
    1. Xu H, Zhao L, Fu H, Xu R, Xie L, Zhang K, et al. Prognostic value of cardiac MRI late gadolinium enhancement in patients with peripartum cardiomyopathy: a retrospective study. Current Problems in Cardiology 2023;48(4):101587. [DOI: ] - PubMed
Yang 2013
    1. Yang Y, Rodriguez JE, Kitsis RN. A microRNA links prolactin to peripartum cardiomyopathy. Journal of Clinical Investigation 2013;123(5):1925-1927. [DOI: 10.1172/JCI69286] - DOI - PMC - PubMed
Zhang 2023
    1. Zhang Z, Zheng W, Chen M, Xie Q, Huang M, Li W, et al. A new risk score for the assessment of outcomes for Chinese patients with peripartum cardiomyopathy. Heart & Lung 2023;60:81-86. [DOI: 10.1016/j.hrtlng.2023.02.021] - DOI - PubMed

References to other published versions of this review

Carlin 2010
    1. Carlin AJ, Alfirevic Z, Gyte GML. Interventions for treating peripartum cardiomyopathy to improve outcomes for women and babies. Cochrane Database of Systematic Reviews 2010. [DOI: 10.1002/14651858.CD008589.pub2] - DOI - PMC - PubMed

LinkOut - more resources